1 |
Abramov AY, Canevari L, Duchen MR. Changes in intracellular calcium and glutathione in astrocytes as the primary mechanism of amyloid neurotoxicity. J Neurosci 23: 5088- 5095, 2003
DOI
PUBMED
|
2 |
Bachurin SO, Shevtsova EP, Kireeva EG, Oxenkrug GF, Sablin SO. Mitochondria as a target for neurotoxins and neuroprotective agents. Ann N Y Acad Sci 993: 334- 344, 2003
DOI
ScienceOn
|
3 |
Inoue I, Nagase H, Kishi K, Higuti T. ATP-sensitive channel in the mitochondrial inner membrane. Nature 352: 244- 247, 1991
DOI
ScienceOn
|
4 |
Liu GS, Downey JM, Cohen MV. Adenosine, ischemia and preconditioning, In: Jacobson KA, Jarvis MF ed, Purinergic Approaches in Experimental Therapeutics. 1st ed. Wiley-Liss, NY, p 153-172, 1997
|
5 |
Morgan DM. Tetrazolium (MTT) assay for cellular viability and activity. Methods Mol Biol 79: 179- 183, 1998
PUBMED
|
6 |
Olah ME, Stiles GL. Adenosine receptor subtypes: characterization and therapeutic regulation. Ann Rev Pharmacol Toxicol 35: 581- 606, 1995
DOI
ScienceOn
|
7 |
Rudolphi KA, Schubert P, Parkinson FE, Fredholm BB. Neuroprotective role of adenosine in cerebral ischaemia. Trends Pharmacol Sci 13 :439- 445, 1992
DOI
ScienceOn
|
8 |
Szewczyk A, Marban E. Mitochondria: a new target for channel openers? Trends Pharmacol Sci 20: 157- 161, 1999
DOI
ScienceOn
|
9 |
Von Lubitz DK, Diemer NH. Self-defense of the brain: adenosinergic strategies. In: Marangos PJ, Lal H ed, Emerging Strategies in Neuroprotection. Birkhauser, Boston, MA, p 151- 186, 1990
|
10 |
Jacobson KA, Park KS, Jiang JL, Kim YC, Olah ME, Stiles GL, Ji XD. Pharmacological characterization of novel adenosine receptor-selective antagonists. Neuropharmacol 36: 1157- 1165, 1997
DOI
ScienceOn
|
11 |
Stiles GL. Adenosine receptors. J Biol Chem 267: 6451- 6454, 1992
PUBMED
|
12 |
Phillis JW. Adenosine, inosine, and oxypurines in cerebral ischemia. In: Schurr A, Rigor BM ed, Cerebral Ischemia and Resusscitation. 1st ed. CRC Press, Boca Raton, FL p 189- 204, 1990
|
13 |
Bradford MM. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 72: 248- 254, 1976
DOI
PUBMED
ScienceOn
|
14 |
Von Lubitz DK, Carter MF, Deutsch SI, Lin RC, Mastropaolo J, Meshulam Y, Jacobson KA. The effects of adenosine A3 receptor stimulation on seizures in mice. Eur J Pharmacol 275: 23- 29, 1995b
DOI
ScienceOn
|
15 |
Pike CJ, Burdick D, Walencewicz AJ, Glabe CG, Cotman CW. Neurodegeneration induced by beta-amyloid peptides in vitro: the role of peptide assembly state. J Neurosci 13: 1676- 1687, 1993
DOI
PUBMED
|
16 |
Smale G, Nichols NR, Brady DR, Finch CE, Horton WE Jr. Evidence for apoptotic cell death in Alzheimer's disease. Exp Neurol 33: 225-230, 1995
DOI
ScienceOn
|
17 |
Von Lubitz DK, Carter MF, Beenhakker M, Lin RC, Jacobson KA. Adenosine: a prototherapeutic concept in neurodegeneration. Ann N Y Acad Sci 765: 163-178, 1995a
DOI
PUBMED
|
18 |
Pike CJ, Walencewicz-Wasserman AJ, Kosmoski J, Cribbs DH, Glabe CG, Cotman CW. Structure-activity analyses of betaamyloid peptides: contributions of the beta 25-35 region to aggregation and neurotoxicity. J Neurochem 64: 253- 265, 1995
DOI
PUBMED
ScienceOn
|
19 |
Anandatheerthavarada HK, Biswas G, Robin MA, Avadhani NG. Mitochondrial targeting and a novel transmembrane arrest of Alzheimer's amyloid precursor protein impairs mitochondrial function in neuronal cells. J Cell Biol 161: 41- 54, 2003
DOI
ScienceOn
|
20 |
Andoh T, Ishiwa D, Kamiya Y, Echigo N, Goto T, Yamada Y. A1 adenosine receptor-mediated modulation of neuronal ATP-sensitive K channels in rat substantia nigra. Brain Res 1124: 55- 61, 2006
DOI
ScienceOn
|
21 |
Lassmann H, Bancher C, Breitschopf H, Wegiel J, Bobinski M, Jellinger K, Wisniewski HM. Cell death in Alzheimer's disease evaluated by DNA fragmentation in situ. Acta Neuropathol 89: 35- 41, 1995
DOI
ScienceOn
|
22 |
Kontush A. Amyloid-beta: an antioxidant that becomes a prooxidant and critically contributes to Alzheimer's disease. Free Radic Biol Med 31: 1120- 1131, 2001
DOI
ScienceOn
|
23 |
Kroemer G, Dallaporta B, Resche-Rigon M. The mitochondrial death/life regulator in apoptosis and necrosis. Annu Rev Physiol 60: 619- 642, 1998
DOI
ScienceOn
|
24 |
Lemasters JJ, Nieminen AL, Qian T, Trost LC, Elmore SP, Nishimura Y, Crowe RA, Cascio WE, Bradham CA, Brenner DA, Herman B. The mitochondrial permeability transition in cell death: a common mechanism in necrosis, apoptosis and autophagy. Biochim Biophys Acta 1366: 177- 196, 1998
DOI
ScienceOn
|
25 |
Ukena D, Shamim MT, Padgett W, Daly JW. Analogs of caffeine: antagonists with selectivity for adenosine receptors. Life Sci 39: 743-750, 1986
DOI
ScienceOn
|
26 |
Moos WH, Szotek DS, Bruns RF. -cycloalkyladenosines. Potent, A1-selective adenosine agonists. J Med Chem 28: 1383- 1384, 1985
DOI
PUBMED
|
27 |
Haleen SJ, Steffen RP, Hamilton HW. PD 116948, a highly selective adenosine receptor antagonist. Life Sci 140: 555- 561, 1987
|
28 |
Nagele RG, D'Andrea MR, Lee H, Venkataraman V, Wang HY. Astrocytes accumulate A beta 42 and give rise to astrocytic amyloid plaques in Alzheimer disease brains. Brain Res 971: 197- 209, 2003
DOI
ScienceOn
|
29 |
Daly JW. Adenosine receptors: targets for future drugs. J Med Chem 25: 197- 207, 1982
DOI
PUBMED
|
30 |
Selkoe DJ. Amyloid beta-protein precursor: new clues to the genesis of Alzheimer's disease. Curr Opin Neurobiol 4: 708- 716, 1994
DOI
PUBMED
ScienceOn
|
31 |
Lyman GE, DeVincenzo JP. Determination of picogram amounts of ATP using the luciferin-luciferase enzyme system. Anal Biochem 21: 435- 443, 1967
DOI
ScienceOn
|